Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 6/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | ADH1B | P00325 | 1/20 | 0.52 |
| ▸ | ADH1C | P00326 | 1/20 | 0.52 |
| ▸ | ADH1A | P07327 | 1/20 | 0.52 |
| ▸ | ADH7 | P40394 | 1/20 | 0.52 |
| ▸ | ST14 | Q9Y5Y6 | 4/20 | 0.48 |
| ▸ | F2 | P00734 | 5/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | C1S | P09871 | 1/20 | 0.47 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3306120 | 0.83 | ADH1B (0.53) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL14542686 | 0.81 | ADH1B (0.52) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL21697134 | 0.80 | ADH1B (0.50) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL7428912 | 0.80 | PRSS1 (0.50) | PRSS1PRSS2PRSS3F10LOXL2 | |
| SCHEMBL8763196 | 0.79 | ADH1B (0.76) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL4720677 | 0.77 | ADH1B (0.61) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL12085592 | 0.76 | PRSS1 (0.56) | PRSS1PRSS2PRSS3F10LOXL2 | |
| SCHEMBL1445807 | 0.76 | PRSS1 (0.53) | PRSS1PRSS2PRSS3F10LOXL2 | |
| SCHEMBL13714812 | 0.76 | PRSS1 (0.53) | PRSS1PRSS2PRSS3F10LOXL2 | |
| SCHEMBL1445939 | 0.75 | PRSS1 (0.48) | PRSS1PRSS2PRSS3F10LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658685-B2 | Methods for treatment of kallikrein-related disorders | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2051707-B1 | INHIBITORS OF PLASMA KALLIKREIN | ACTIVESITE PHARMACEUTICALS INC (US) | 2013-07-17 | — | — | EP | disclosed |
| US-8258170-B2 | Inhibitors of plasma kallikrein | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110301215-A1 | INHIBITORS OF PLASMA KALLIKREIN | Activesite Phamaceuticals, Inc. (US) | 2011-12-08 | — | — | US | disclosed |
| US-7977380-B2 | Inhibitors of plasma kallikrein | Activesite Pharmaceticals, Inc. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110065757-A1 | METHODS FOR TREATMENT OF KALLIKREIN-RELATED DISORDERS | JOSKIN DIABETES CENTER (US) | 2011-03-17 | — | — | US | disclosed |
| EP-2259679-A1 | METHODS FOR TREATMENT OF KALLIKREIN-RELATED DISORDERS | JOSLIN DIABETES CENTER (US) | 2010-12-15 | — | — | EP | disclosed |
| US-20100130563-A1 | INHIBITORS OF PLASMA KALLIKREIN | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-7625944-B2 | Inhibitors of plasma kallikrein | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2009097141-A1 | METHODS FOR TREATMENT OF KALLIKREIN-RELATED DISORDERS | JOSLIN DIABETES CENTER (US) | 2009-08-06 | — | — | WO | disclosed |
| CN-101495468-A | Inhibitors of plasma kallikrein | ACTIVESITE PHARMACEUTICALS INC (US) | 2009-07-29 | — | — | CN | disclosed |
| EP-2051707-A2 | INHIBITORS OF PLASMA KALLIKREIN | Activesite Pharmaceuticals, Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20080038276-A1 | INHIBITORS OF PLASMA KALLIKREIN | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| WO-2008016883-A2 | INHIBITORS OF PLASMA KALLIKREIN | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-1995018619-A9 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-10-21 | — | — | WO | disclosed |
| US-6117866-A | Bicyclic fibrinogen antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| EP-0738150-A4 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0738150-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-10-23 | — | — | EP | disclosed |
| WO-1995018619-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065757-A1 | METHODS FOR TREATMENT OF KALLIKREIN-RELATED DISORDERS | KLKB1, SERPINE1, KLK1 | PRSS1 64/4885PRSS2 149/4885PRSS3 156/4885 |
| US-20080038276-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK5 | PRSS1 48/4885PRSS2 97/4885PRSS3 80/4885 |
| US-20100130563-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK5 | PRSS1 48/4885PRSS2 97/4885PRSS3 80/4885 |
| US-20110301215-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK5 | PRSS1 48/4885PRSS2 97/4885PRSS3 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.